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the nature of the NPC2-NgBR interaction
will come from the metabolic labeling
studies, coupled with examination of the
mode of NPC2 degradation. Such studies
will establish whether, in the absence of
NgBR, NPC2 is degraded within the ER
or is targeted for proteosomal degrada-
tion from the lysosome. Because NPC2-
mediated sterol transfer in vitro does not
require NgBR (Cheruku et al., 2006;
Infante et al., 2008), NgBRmay principally
exert its effect by retaining sufficient
levels of NPC2 protein, which one could
hypothesize may be rate limiting, to facil-
itate rapid intralysosomal transfer of lipo-
protein-derived cholesterol from internal
membranes to NPC1 at the limiting lyso-
somal membrane.
The NPC1-NPC2 pathway acts as
a critical checkpoint for sensing the flux
of lipoprotein-derived cholesterol through
endocytic pathway. This is achieved
through delivery of free cholesterol to the
ER sterol-sensing machinery and by
promoting synthesis of side-chain oxy-
sterols, which act cooperatively with ER
membrane cholesterol to downregulate
cholesterol synthesis and uptake (Frolov
et al., 2003). Regulation of NPC2 protein
levels by NgBR would potentially offer
an additional point of regulation to the
diverse transcriptional and posttransla-
tional regulatory pathways that contribute
to maintenance of cellular cholesterol
balance. In this event, it would be ex-
pected that NgBR protein levels might
be subject to sterol regulation, perhaps
at the level of protein expression or even
subcellular localization.
The study by Harrison et al. under-
scores the power of unbiased genetic
screens. In future studies, investigation
of the specificity and nature of the
NPC2-NgBR binding will shed light onto
the physiological relevance of this unan-
ticipated protein interaction. It will be
instructive to define the regions of NPC2
necessary to support NgBR binding and
whether glycosylation-deficient forms of
NPC2 (i.e., Asn-39 and Asn-116 mutants)
permit binding to NgBR. A critical
question is whether the stabilizing effect
of NgBR is specific for NPC2 or more
broadly extends to other prenlyated or
N-glycosylated proteins. If NgBR ulti-
mately is shown to regulate NPC2
protein levels in a specific and possibly
sterol-regulated fashion, then the NgBR-
NPC2 interaction may serve as a molec-
ular rheostat that responds to the magni-
tude of lipoprotein cholesterol flux
through the endocytic pathway. Thus,
regulation of NPC2 protein stability would
appear to provide yet another layer of
control to limit free cholesterol-mediated
cytotoxicity.
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In this issue of Cell Metabolism, Thomas et al. (2009) show that specific activation of the bile-acid-activated
G protein-coupled receptor TGR5 improves pancreatic and hepatic function and impairs the development of
obesity following administration of a high-fat diet.Despite the obvious advantage of in-
creased exercise and restricted calorie
intake and the availability of treatments
that target obesity and associated disor-
ders, the worldwide fat epidemic con-
tinues unabated. Recent studies sug-162 Cell Metabolism 10, September 2, 2009gest that the development of bile acid
mimetics may prove useful in the treat-
ment of obesity-related disorders. In a
tour de force published in this issue of
Cell Metabolism, Thomas et al. (2009)
demonstrate that activation of TGR5 pro-ª2009 Elsevier Inc.vides significant protection from many
physiological changes that normally arise
from ingestion of a high-fat diet.
This is the latest in a series of unex-
pected findings that have expanded the
role of bile acids from simple detergents
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Figure 1. Overview of the Effects of Bile Acid Activation of TGR5 and FXR in the Gut
Bile acids present in the intestine activate both TGR5 on the surface of enteroendocrine L cells and the nuclear receptor FXR in enterocytes. Ninety-five percent of
the bile acids entering the intestinal lumen from the gall bladder are subsequently resorbed via the apical sodium-dependent bile acid transporter (ASBT), leading
to activation of the FXR:RXR heterodimer bound to the FXR response element (FXRE) and induction of target genes. Bile acids in the intestinal lumen also activate
TGR5 on the surface of enteroendocrine L cells, leading to an increase in oxidative phosphorylation and the ratio of ATP:ADP. The increased levels of ATP are
thought to inhibit the ATP-sensitive potassium channel, leading to a depolarization of the cell membrane and opening of calcium channels. TGR5 activation also
activates adenylate cyclase (Ad. Cyclase), thus increasing cellular cAMP levels. Increases in intracellular calcium and cAMP both lead to increased secretion of
GLP-1 from L cells. Secreted GLP-1 has a number of effects. It augments glucose-dependent insulin release from b cells, it promotes b cell development, and it
stimulates afferent nerves. GLP-1 can also induce satiety, and it has neuro- and cardioprotective roles.necessary for lipid absorption to that of
potent hormones. In 1999, three groups
made the remarkable observation that
specific bile acids bound to and activated
the nuclear receptor FXR, leading to in-
creased transcription of specific target
genes (Figure 1). These genes control a
number of diverse pathways, including
bile acid, cholesterol, and glucosemetab-
olism (reviewed in Zhang and Edwards,
2008; Lefebvre et al., 2009). Subsequent
studies demonstrated that bile acids
also activated three other nuclear recep-
tors (VDR, PXR, and CAR), consistent
with pleiotropic effects in vivo (Schmidt
and Mangelsdorf, 2008; Zhang and
Edwards, 2008).
In yet another surprise, specific bile
acids were shown in 2002–2003 to acti-
vate a cell surface G protein-coupled re-
ceptor, nownamedTGR5, and to increase
cellular cAMP levels (Maruyama et al.,
2006; Kawamata et al., 2003). TGR5 ex-
pression levels vary greatly from tissue to
tissue. For example, high expression is
observed in the intestine and gall bladder,which are normally exposed to high levels
of bile acids circulating in the enterohe-
patic circulation, whereas low levels of
TGR5 are present in muscle and BAT,
tissues that are exposed to lower levels
of bile acids present in peripheral blood.
TGR5 may, therefore, have different
effectsdependingon thecell type. Indeed,
bile acid activation of TGR5 in either BAT
or muscle cells was previously shown to
result in increased cAMP levels and acti-
vation of type 2 thyroid hormone deiodi-
nase (D2) that converts inactive T4 to the
active thyroid hormone T3. Consistent
with this finding, a diet enriched in bile
acids increased both D2 in BAT and
energy expenditure and resulted in resis-
tance to fat-induced obesity (Watanabe
et al., 2006). In contrast, activation of
TGR5 in enteroendocrine L cells that are
scattered throughout the jejunum, ileum,
and colon stimulates the secretion of the
incretin glucagon-like peptide-1 (GLP-1)
(reviewed in Thomas et al., 2008).
Thomas et al. (2009) now report on
additional studies aimed at delineatingCell Metabolism 10,the physiological function of TGR5 (Fig-
ure 1). The synthesis of INT-777, a novel
bile acid mimetic that activates TGR5,
but not FXR (Pellicciari et al., 2007),
and the generation of both gain-of-func-
tion (Tgr5-Tg) and Tgr5/ mice (Thomas
et al., 2009) enabled complementary
and extensive in vitro and in vivo studies.
Overexpression/activation of TGR5 was
shown to improve liver function, protect
pancreatic islets from high-fat-induced
hypertrophy and insulin reduction, im-
prove glucose tolerance and insulin
sensitivity in obese mice, and reduce
hepatic steatosis and obesity in fat-fed
mice.
One important player in these effects
produced by activation of TGR5 in vivo
appears to be the incretin GLP-1. Impor-
tantly, administration of drugs that either
impair GLP-1 degradation in the blood or
activate the GLP-1 receptor are currently
used clinically to improve insulin sensi-
tivity in type 2 diabetics (Reimann et al.,
2008). Thus, understanding the mecha-
nisms controlling GLP-1 release isSeptember 2, 2009 ª2009 Elsevier Inc. 163
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the development of novel clinical treat-
ments.
The combined approaches by Thomas
et al. (2009) show that activation of
TGR5 results in increases in intracellular
levels of cAMP, oxygen consumption,
cytochrome c oxidase (thus linking TGR5
with mitochondrial function), and the
ATP:ADP ratio (Figure 1). The authors pro-
pose that the increase in ATP:ADP could
account for the inactivation of the KATP
channel, membrane depolarization, and
subsequent opening of a calcium-gated
voltage channel on enteroendocrine L
cells (Figure 1). Importantly, the increase
in cellular calcium levels in enteroendo-
crine L cells stimulates GLP-1 secretion.
The authors also show that oral adminis-
tration of either glucose or a high-fat
meal to Tgr5-Tg mice improved glucose
tolerance and increased GLP-1 secretion.
One possibility is that the high-fat meal
caused the gall bladder to contract, thus
increasing bile acid levels in the intestinal
lumen and activating TGR5 on L cells.
Surprisingly, although fat-fed Tgr5-Tg
mice exhibited higher energy expendi-
ture, they did not lose bodyweight relative
to control mice. The authors suggest that
this may be a result of the decreased
locomotion of Tgr5-Tg mice, a finding
consistent with the known hyperactivity
observed in GLP-1 knockout mice.
To directly address the effects of phar-
macological activation of TGR5, ThomasMetabolism by Re
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Drosophila melanogaster produce
growth, metabolism, aging, and re
describe how secretion of insulin-lik
tissue) in response to dietary amino
Diseases of metabolism are appearing in
alarming proportions in many societies.
These complex pathologies reflect a
164 Cell Metabolism 10, September 2, 2009et al. (2009) fed wild-type mice a high-fat
diet to promote obesity and generate
symptoms normally associated with
diabetes. Some of the fat-fed mice were
also treated with the TGR5 agonist
INT-777. The results were striking, as
compared to fat-fed controls, the INT-
777-treated mice exhibited a 17% reduc-
tion in body weight and had reduced
adiposity, improved liver function, less
steatosis (fat in the liver), decreased
plasma levels of triglycerides and free
fatty acids, and an improved glu-cose
tolerance test. Importantly, food intake,
which can be repressed by high levels of
GLP-1, was unaffected by INT-777
treatment. Indeed, calorimetric studies
indicate that the changes in body weight
are likely a result of increased energy
expenditure.
The Tgr5-floxed mice generated in the
current study provide a new resource, as
they can now be used to generate mice
lacking TGR5 in specific cell types. In
this regard, it will be particularly inter-
esting to assess whether the physiolog-
ical effects of INT-777 are attenuated
following deletion of TGR5 from enteroen-
docrine L cells or from pancreatic b cells if
TGR5 is expressed in the latter cells.
In conclusion, studies during the last
decade have identified bile acids as
potent hormones that activate nuclear
receptors and a G protein-coupled re-
ceptor. Hopefully, these studies will lead
to the development of specific agonistsmote Control
insulin-like peptides in specialized
production. In this issue of Cell M
e peptides is remotely controlled by
acids.
loss of homeostasis between our environ-
ment, endocrine physiology, and molec-
ular mechanisms within cells. Scientists
ª2009 Elsevier Inc.for FXR or TGR5 that will prove efficacious
in the treatment of various metabolic
disorders.
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